Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabosili combined with endocrine therapy in advanced HR+/HER2- breast cancer
ChiCTR2200057500Phase 4Not yet recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dalpiciclib in breast cancer, sponsored by Hunan Cancer Hospital. Primary endpoint: Adverse events. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
dalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2200057500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057500.